This JAK2/MDM2 pathway has been clinically reinforced since the MDM2 [9] inhibitor (Nutlin-3) significantly reduces MPN-CD34+ cell proliferation when combined with IFN-α [9]. This evidence concerns the gene JAK2 and myeloproliferative disorder.